Advertisement

Annals of Surgical Oncology

, Volume 25, Issue 12, pp 3639–3646 | Cite as

Recurrence Risk Based on Pathologic Stage After Neoadjuvant Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: Implications for Risk-Based Postoperative Surveillance Strategies

  • Sha Zhou
  • Shiliang Liu
  • Li Zhang
  • Suping Guo
  • Jingxian Shen
  • Qiaoqiao Li
  • Hong Yang
  • Yanfen Feng
  • Mengzhong Liu
  • Steven H. Lin
  • Mian Xi
Thoracic Oncology
  • 146 Downloads

Abstract

Background

This study aimed to investigate the association between pathologic stage and recurrence risk and survival for patients with esophageal squamous cell carcinoma (SCC) after neoadjuvant chemoradiotherapy (CRT).

Methods

This retrospective analysis consisted of two patient cohorts who had esophageal SCC treated with neoadjuvant CRT and esophagectomy at two major academic institutions between 2002 and 2015. The study included 174 patients in the training cohort and 51 patients in the validation cohort. Recurrence pattern, frequency, and survival according to pathologic stage were analyzed.

Results

After surgery, patients in the training cohort had the following pathologic categories: stage 0 (44.8%, n = 78), stage 1 (6.9%, n = 12), stage 2 (35.6%, n = 62), and stage 3 (12.6%, n = 22). During a median follow-up period of 53.9 months, recurrences developed in 59 patients. The recurrence rates were 22.2% for stages 0 and 1, 38.7% for stage 2, and 68.2% for stage 3 (stages 0 and 1 vs. stage 2 [P = 0.028], stages 0 and 1 vs. stage 3 [P < 0.001], and stage 2 vs. stage 3 [P = 0.017]). More than 20% of patients with stages 0 and 1 or 2 disease experienced late relapses after 3 years of follow-up evaluation, whereas all the patients with pathologic stage 3 had recurrences within 2 years. The 5-year recurrence-free survival rate was 74.7% for the patients with pathologic stage 0 or 1, 61.4% for those with stage 2, and 20.9% for those with stage 3 disease (P < 0.001). These major findings were successfully reproduced in the Western validation cohort.

Conclusions

Patients with a higher pathologic stage were associated with a significantly higher risk of recurrences and worse survival. Multicenter and prospective validation is warranted.

Notes

Acknowledgment

This work was supported by Grants from the Natural Science Foundation of Guangdong Province (2015A030310044), the Science and Technology Planning Project of Guangdong Province (2013B021800156), and the Guangdong Esophageal Cancer Institute Science and Technology Program (M201715).

Disclosure

Steven H. Lin has received research funding from STCube Pharmaceuticals, Peregrine Pharmaceuticals, Hitachi Chemical Diagnostics, and Roche/Genentech, is on the advisory board for AstraZeneca, and has received honoraria from US Oncology and ProCure. The other authors have no conflicts of interest to declare.

Supplementary material

10434_2018_6736_MOESM1_ESM.docx (24 kb)
Supplementary material 1 (DOCX 24 kb)

References

  1. 1.
    Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.CrossRefGoogle Scholar
  2. 2.
    van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074–84.CrossRefGoogle Scholar
  3. 3.
    Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12:681–92.CrossRefGoogle Scholar
  4. 4.
    Shapiro J, van Lanschot JJ, Hulshof MC, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16:1090–8.CrossRefGoogle Scholar
  5. 5.
    Oppedijk V, van der Gaast A, van Lanschot JJ, et al. Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials. J Clin Oncol. 2014;32:385–91.CrossRefGoogle Scholar
  6. 6.
    Sudo K, Taketa T, Correa AM, et al. Locoregional failure rate after preoperative chemoradiation of esophageal adenocarcinoma and the outcomes of salvage strategies. J Clin Oncol. 2013;31:4306–10.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Robb WB, Messager M, Dahan L, et al. Patterns of recurrence in early-stage oesophageal cancer after chemoradiotherapy and surgery compared with surgery alone. Br J Surg. 2016;103:117–25.CrossRefGoogle Scholar
  8. 8.
    van Hagen P, Wijnhoven BP, Nafteux P, et al. Recurrence pattern in patients with a pathologically complete response after neoadjuvant chemoradiotherapy and surgery for oesophageal cancer. Br J Surg. 2013;100:267–73.CrossRefGoogle Scholar
  9. 9.
    Abate E, DeMeester SR, Zehetner J, et al. Recurrence after esophagectomy for adenocarcinoma: defining optimal follow-up intervals and testing. J Am Coll Surg. 2010;210:428–35.CrossRefGoogle Scholar
  10. 10.
    Xi M, Hallemeier CL, Merrell KW, et al. Recurrence risk stratification after preoperative chemoradiation of esophageal adenocarcinoma. Ann Surg. 2018;268(2):289–95.CrossRefGoogle Scholar
  11. 11.
    National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Esophageal and Esophagogastric Junction Cancers: V.2.2018. Fort Washington, PA: NCCN.Google Scholar
  12. 12.
    Taketa T, Sudo K, Correa AM, et al. Post-chemoradiation surgical pathology stage can customize the surveillance strategy in patients with esophageal adenocarcinoma. J Natl Compr Cancer Netw. 2014;12:1139–44.CrossRefGoogle Scholar
  13. 13.
    Davies AR, Gossage JA, Zylstra J, et al. Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction. J Clin Oncol. 2014;32:2983–90.CrossRefGoogle Scholar
  14. 14.
    McNamara MJ, Rybicki LA, Sohal D, et al. The relationship between pathologic nodal disease and residual tumor viability after induction chemotherapy in patients with locally advanced esophageal adenocarcinoma receiving a tri-modality regimen. J Gastrointest Oncol. 2016;7:196–205.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Siewert JR, Ott K. Are squamous and adenocarcinomas of the esophagus the same disease? Semin Radiat Oncol. 2007;17:38–44.CrossRefGoogle Scholar
  16. 16.
    Deng J, Chen H, Zhou D, et al. Comparative genomic analysis of esophageal squamous cell carcinoma between Asian and Caucasian patient populations. Nat Commun. 2017;8:1533.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Edge SB, Byrd DR, Compton CC, et al (eds). AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2010.Google Scholar
  18. 18.
    Robb WB, Dahan L, Mornex F, et al. Impact of neoadjuvant chemoradiation on lymph node status in esophageal cancer: post hoc analysis of a randomized controlled trial. Ann Surg. 2015;261:902–8.CrossRefGoogle Scholar
  19. 19.
    Tu CC, Hsu PK, Chien LI, et al. Prognostic histological factors in patients with esophageal squamous cell carcinoma after preoperative chemoradiation followed by surgery. BMC Cancer. 2017;17:62.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Wang CC, Cheng JC, Tsai CL, et al. Pathological stage after neoadjuvant chemoradiation and esophagectomy superiorly predicts survival in patients with esophageal squamous cell carcinoma. Radiother Oncol. 2015;115:9–15.CrossRefGoogle Scholar
  21. 21.
    Steffen T, Dietrich D, Schnider A, et al. Recurrence patterns and long-term results after induction chemotherapy, chemoradiotherapy, and curative surgery in patients with locally advanced esophageal cancer. Ann Surg. 2017.  https://doi.org/10.1097/SLA.0000000000002435.CrossRefGoogle Scholar
  22. 22.
    Wang LD, Zhou FY, Li XM, et al. Genome-wide association study of esophageal squamous cell carcinoma in Chinese subjects identifies susceptibility loci at PLCE1 and C20orf54. Nat Genet. 2010;42:759–63.CrossRefGoogle Scholar
  23. 23.
    Zhang J, Jiang Y, Wu C, et al. Comparison of clinicopathologic features and survival between eastern and western population with esophageal squamous cell carcinoma. J Thorac Dis. 2015;7:1780–6.PubMedPubMedCentralGoogle Scholar

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  • Sha Zhou
    • 1
  • Shiliang Liu
    • 1
  • Li Zhang
    • 1
  • Suping Guo
    • 1
  • Jingxian Shen
    • 2
  • Qiaoqiao Li
    • 1
  • Hong Yang
    • 3
  • Yanfen Feng
    • 4
  • Mengzhong Liu
    • 1
  • Steven H. Lin
    • 5
  • Mian Xi
    • 1
  1. 1.Department of Radiation Oncology, Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangdong Esophageal Cancer InstituteSun Yat-sen UniversityGuangzhouChina
  2. 2.Imaging Diagnosis and Interventional Center, Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangdong Esophageal Cancer InstituteSun Yat-sen UniversityGuangzhouChina
  3. 3.Department of Thoracic Oncology, Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangdong Esophageal Cancer InstituteSun Yat-sen UniversityGuangzhouChina
  4. 4.Department of Pathology, Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangdong Esophageal Cancer InstituteSun Yat-sen UniversityGuangzhouChina
  5. 5.Department of Radiation OncologyThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations